Nikko Asset Management Reports 5.4% Holding in 10x Genomics (TXG)

Rhea-AI Filing Summary

Nikko Asset Management Americas, Inc. filed a Schedule 13G reporting beneficial ownership of 6,009,653 shares of 10x Genomics, Inc. Class A common stock, representing 5.4% of the class. The filing discloses shared voting power for 5,605,769 shares and shared dispositive power for 6,009,653 shares, with no sole voting or dispositive power reported.

The statement includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The filing identifies the filer and issuer addresses and is signed by Gary L. Beckham, Chief Compliance Officer.

Positive

• Material ownership disclosed: 6,009,653 shares representing 5.4% of Class A common stock
• Passive-holder certification: filer states shares were acquired and are held in the ordinary course and not to influence control

Negative

• No sole voting or dispositive power: the filer reports 0 shares of sole voting power and 0 shares of sole dispositive power

Insights

Financial Analyst

TL;DR: Nikko AM reports a material, passive 5.4% stake in TXG with shared voting and dispositive power; filing signals non-control ownership.

The Schedule 13G documents a 5.4% beneficial holding (6,009,653 shares) in 10x Genomics Class A stock and reports shared voting power over 5,605,769 shares. Because the filer includes the certification that the holdings were acquired and are held in the ordinary course and not to influence control, this is a passive disclosure rather than an active control filing. For investors, a >5% passive stake is material for ownership transparency but does not, by itself, indicate strategic control or a change in governance.

Corporate Governance Expert

TL;DR: The Schedule 13G filing shows material ownership without sole control; governance influence appears limited given the filer’s certification.

The filing shows no sole voting or dispositive power and explicitly certifies ordinary-course, non-control intent. Shared voting power of 5,605,769 shares may allow coordination with other holders but, per this filing, the filer disclaims intent to change control. From a governance perspective, this is a transparency event required by securities rules rather than an assertion of board or control ambitions.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

10x Genomics, Inc.

(Name of Issuer)

Class A common stock, par value $0.00001 per share

(Title of Class of Securities)

88025U109

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 88025U109

1

Names of Reporting Persons

Nikko Asset Management Americas, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,605,769.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,009,653.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,009,653.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: 10x Genomics, Inc.
(b)	Address of issuer's principal executive offices: 6230 STONERIDGE MALL ROAD, PLEASANTON, California, 94588
Item 2.
(a)	Name of person filing: Nikko Asset Management Americas, Inc.
(b)	Address or principal business office or, if none, residence: 605 Third Avenue, 38th Floor, New York, NY 10158
(c)	Citizenship: USA
(d)	Title of class of securities: Class A common stock, par value $0.00001 per share
(e)	CUSIP No.: 88025U109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 6,009,653
(b)	Percent of class: 5.4%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 5,605,769
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 6,009,653
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Exhibit A.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit A.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Nikko Asset Management Americas, Inc.

Signature:	/s/ Gary L. Beckham
Name/Title:	Gary L. Beckham, Chief Compliance Officer
Date:	08/11/2025

FAQ

How many 10x Genomics (TXG) shares does Nikko Asset Management Americas report owning?

The filing reports beneficial ownership of 6,009,653 shares of 10x Genomics Class A common stock.

What percentage of TXG does Nikko AM hold according to this Schedule 13G?

Nikko Asset Management Americas reports holding 5.4% of the Class A common stock.

Does Nikko AM have sole voting or dispositive power over these TXG shares?

No; the filer reports 0 shares of sole voting power and 0 shares of sole dispositive power, with shared powers reported instead.

Does the filing indicate Nikko AM seeks to influence control of 10x Genomics (TXG)?

The filing includes a certification that the securities were acquired and are held in the ordinary course and not for the purpose of changing or influencing control.

Who signed the Schedule 13G for Nikko Asset Management Americas and when?

The filing is signed by Gary L. Beckham, Chief Compliance Officer, with a signature date of 08/11/2025.